Marker Therapeutics, Inc.
MRKR · United States
Share price · MRKR
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when MRKR's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 19 Oct 2026+15.4%
- 16 Oct 2026+13.0%
Nothing announced by MRKR that day or the session before.
- 8 Oct 2026-8.7%
Nothing announced by MRKR that day or the session before.
- 8 Sep 2026+8.5%
Nothing announced by MRKR that day or the session before.
- 24 Aug 2026+7.9%
Nothing announced by MRKR that day or the session before.
- 21 Aug 2026+13.9%
Nothing announced by MRKR that day or the session before.
- 5 Aug 2026-7.3%
Nothing announced by MRKR that day or the session before.
- 3 Aug 2026+8.0%
Nothing announced by MRKR that day or the session before.
- 7 Jul 2026+13.5%
Nothing announced by MRKR that day or the session before.
- 29 Jun 2026+10.6%
Nothing announced by MRKR that day or the session before.
Share of unusual movement by asset
For each asset, the share of MRKR's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(2 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 1 | Six tumor-associated antigensCell therapy | Non-Hodgkin Lymphoma Relapsed/Refractory Non-Hodgkin Lymphoma | |
| Phase 1 | WT1, PRAME, survivin (multiple tumor-associated antigens)Cell therapy | Acute Myeloid Leukemia |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
Quarterly & interim (15)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $1.5M | $12M | $1.8M-$3.7M operating cash flow | report ↗ |
View 14 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q1 | $0.8M | $2.8M | $16M | $3.2M-$1.4M operating cash flow | report ↗ |
| 2025-Q3 | $1.2M | $2.4M | $19M | $2.0M-$2.7M operating cash flow | report ↗ |
| 2025-Q2 | $0.9M | $4.2M | $12M | $4.0M-$1.9M operating cash flow | report ↗ |
| 2025-Q1 | $0.3M | $3.1M | $14M | $4.5M-$5.5M operating cash flow | report ↗ |
| 2024-Q3 | $1.9M | $3.5M | $9.0M | $2.3M$1.2M operating cash flow | report ↗ |
| 2024-Q2 | $1.2M | $2.3M | $7.8M | $2.2M-$3.6M operating cash flow | report ↗ |
| 2024-Q1 | $1.2M | $2.6M | $11M | $2.4M-$3.8M operating cash flow | report ↗ |
| 2023-Q3 | $0.3M | $2.0M | $17M | $3.0M-$1.1M operating cash flow | report ↗ |
| 2023-Q2 | $0.8M | $2.4M | $18M | —-$7.1M operating cash flow | report ↗ |
| 2023-Q1 | $4.7M | $7.3M | $6.4M | $5.0M-$5.9M operating cash flow | report ↗ |
| 2022-Q3 | $4.0M | $7.3M | $18M | $6.9M-$7.7M operating cash flow | report ↗ |
| 2022-Q2 | $0.8M | $6.6M | $26M | $9.2M-$0.8M operating cash flow | report ↗ |
| 2022-Q1 | $1.0M | $7.0M | $29M | $9.9M-$12M operating cash flow | report ↗ |
| 2021-Q3 | — | $6.8M | $49M | $12M-$6.5M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $3.5M | $12M | $17M | $3.0M-$12M operating cash flow | report ↗ |
Marker Therapeutics reported full-year 2025 revenue of $3.55M, down 46.1% YoY, with R&D expenses of $11.8M, down 12.4% YoY. Cash and equivalents totaled $17.04M at year-end, and the company reported a net loss of $12.16M. No analyst consensus comparison was provided.
The company guided that existing cash should fund operations through the fourth quarter of 2026, assuming no additional grant funds. Clinical highlights included an updated Phase 1 APOLLO data readout showing a 66% objective response rate in relapsed non-Hodgkin lymphoma with 50% complete responses, a 78% objective response rate in Hodgkin lymphoma, and dose expansion enrollment in relapsed DLBCL. A Nature Medicine publication highlighted multi-antigen targeted T cells in pancreatic cancer with up to an 84.6% disease control rate, and a company-sponsored pancreatic cancer program is expected to initiate in Q2 2026. The company also advanced a manufacturing collaboration with Cellipont Bioservices and appointed Kathryn Penkus Corzo to the Board of Directors.
Insider transactions
Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2025-11-17 | ELMS STEVE · director | Award / grant (derivative) | 84,411 | — | — | Form 4 |
| 2025-11-17 | Eansor Norman David · director | Award / grant (derivative) | 84,411 | — | — | Form 4 |
| 2025-11-17 | Knobil Katharine · director | Award / grant (derivative) | 84,411 | — | — | Form 4 |
| 2025-11-17 | ELMS STEVE · director | Award / grant (derivative) | 137,330 | — | — | Form 4 |
| 2025-11-17 | Eansor Norman David · director | Award / grant (derivative) | 137,330 | — | — | Form 4 |
| 2025-11-17 | Knobil Katharine · director | Award / grant (derivative) | 137,330 | — | — | Form 4 |
| 2025-10-31 | Vera Juan · director, Chief Executive Officer | Award / grant (derivative) | 250,000 | — | — | Form 4 |
| 2025-10-31 | Corzo Kathryn Penkus · director | Award / grant (derivative) | 147,611 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 36 reporting institutions held 3.9M shares ($5.1M, 23.4% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | NEA Management Company, LLC | 1,625,678 | $2.1M |
| 2 | Blue Owl Capital Holdings LP | 554,250 | $721K |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 389,319 | $506K |
| 4 | Aisling Capital Management LP | 325,370 | $423K |
| 5 | RENAISSANCE TECHNOLOGIES LLC | 175,294 | $228K |
| 6 | GEODE CAPITAL MANAGEMENT, LLC | 160,910 | $209K |
| 7 | OSAIC HOLDINGS, INC. | 93,121 | $121K |
| 8 | VANGUARD FIDUCIARY TRUST CO | 87,269 | $113K |
| 9 | LPL Financial LLC | 83,047 | $108K |
| 10 | XTX Topco Ltd | 63,567 | $83K |
| 11 | TWO SIGMA INVESTMENTS, LP | 61,001 | $79K |
| 12 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 48,780 | $63K |
| 13 | JANE STREET GROUP, LLC | 36,303 | $47K |
| 14 | UBS Group AG | 32,369 | $42K |
| 15 | Invst, LLC | 29,000 | $38K |